StockNews.com initiated coverage on shares of Milestone Scientific (NYSE:MLSS – Free Report) in a report published on Friday. The brokerage issued a hold rating on the stock.
Separately, Benchmark began coverage on shares of Milestone Scientific in a report on Thursday, October 10th. They set a “speculative buy” rating and a $1.25 price objective for the company.
Check Out Our Latest Research Report on MLSS
Milestone Scientific Trading Down 2.1 %
Milestone Scientific (NYSE:MLSS – Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Milestone Scientific had a negative net margin of 54.87% and a negative return on equity of 60.78%. The business had revenue of $1.85 million for the quarter.
Insider Transactions at Milestone Scientific
In other Milestone Scientific news, Director Leonard Osser sold 107,984 shares of the stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $0.93, for a total value of $100,425.12. Following the transaction, the director now owns 4,606,882 shares of the company’s stock, valued at approximately $4,284,400.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 251,106 shares of company stock worth $236,451 in the last ninety days. Insiders own 24.75% of the company’s stock.
Milestone Scientific Company Profile
Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.
See Also
- Five stocks we like better than Milestone Scientific
- 3 Stocks to Consider Buying in October
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Dogs of the Dow Strategy? Overview and Examples
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Milestone Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific and related companies with MarketBeat.com's FREE daily email newsletter.